A Turnaround in Sight for Healthcare?

Sean Laaman and Terence Flynn discuss the healthcare sector's recent rally, driven by favorable macro conditions and improving policy visibility. They address how biopharma is adapting to tariff and drug pricing dynamics, the impact of looming patent expirations on M&A trends, and the compelling valuations of large-cap biopharma. They also explore how potential Fed rate cuts could benefit small and mid-cap biotech companies, the "SMID to BIG" thematic, and the early implications of AI in biotech, while also outlining key risks and catalysts for the SMIDCAP Biotech sector.